Full-Time
Quality Control Laboratory Technician
LFB
1,001-5,000 employees
Public health biopharmaceuticals via plasma-derived products
No salary listed
Alès, France
In Person
Bachelor's
 Biology & Biotech (1) |
|---|
Get referred to LFB
See people who can refer or advise you
- You hold a Bac+2/+3 qualification in pharmaceutical quality control.
- You have successful initial experience in a pharmaceutical quality-control environment.
- Plan and perform analyses for environmental and fluid controls, raw materials, in-process products, and finished products, including recording and entering results and preparing reagents; verify the analyses and, when required, approve the results.
- Perform and/or participate in metrological verification, maintenance, qualification, and/or validation of equipment and premises.
- Participate in workplace training for colleagues.
- Participate in continuous-improvement processes, including 5S.
- Participate in laboratory operations, including reagent management, sample management, and meetings.
LFB is a French biopharmaceutical company that develops and manufactures medicines from plasma and biotech products. It collects plasma, fractionates it into medicines, and also produces recombinant proteins for rare diseases in immunology and hemostasis, sold in many countries. It stands out because it started as a state-initiated public health mission and remains state-owned with the French State as sole shareholder, plus vertical integration through acquisitions of plasma collection firms. Its goal is to ensure a reliable supply of essential medicines for public health while growing as a global biopharma player.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Courcebœufs, France
Founded
1994
Get referred to LFB
See people who can refer or advise you
Simplify's Take
What believers are saying
- Arras released first medicines in 2025, proving commercialization after heavy capital spending.
- LFB signed a 2026 collaboration with Sartorius to accelerate client programs and GMP manufacturing.
- France 2030 funding and the 2026 Alès expansion add capacity and roughly fifty jobs.
What critics are saying
- EFS must raise plasma collections to 1.4 million liters by 2028 or Arras underutilizes.
- LFB BIOMANUFACTURING still depends on Sartorius for cell line development, limiting full-stack control.
- A single French industrial base creates existential exposure to contamination, recalls, or regulatory shutdowns.
What makes LFB unique
- French state-owned sole domestic plasma fractionator anchors national medicine supply.
- Arras plant, authorized in 2025, centralizes production and triples plasma-derived capacity.
- Europlasma and Amber Plasma give LFB 24 Central European collection centers.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Remote Work Options
Unlimited Paid Time Off
Flexible Work Hours
Paid Vacation
Hybrid Work Options
Wellness Program
Mental Health Support
Phone/Internet Stipend
Home Office Stipend
Stock Options
Company Equity
Conference Attendance Budget
Family Planning Benefits
Fertility Treatment Support
Professional Development Budget
Education allowance
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 7%1 year growth
↑ 7%2 year growth
↑ 6%Title: "LFB Acquires Amber Plasma in the Czech Republic" LFB and its subsidiary Europlasma have acquired Amber Plasma, which operates 12 plasma collection centers in the Czech Republic. This acquisition increases Europlasma's total to 24 centers in Central Europe, enhancing LFB's plasma collection capacity. The move supports LFB's goal to meet growing patient demand and will aid in the launch of a new production site in Arras, France, tripling its medication production capacity.